IL-10-conditioned dendritic cells prevent autoimmune diabetes in NOD and humanized HLA-DQ8/RIP-B7.1 mice
- 1 June 2011
- journal article
- Published by Elsevier in Clinical Immunology
- Vol. 139 (3) , 336-349
Abstract
No abstract availableKeywords
Funding Information
- Ministry of Education, Culture, Sports, Science and Technology (18590990)
- Juvenile Diabetes Research Foundation United States of America (4-2007-1059, P32 DK 45735)
This publication has 56 references indexed in Scilit:
- Cellular immune response to cryptic epitopes during therapeutic gene transferProceedings of the National Academy of Sciences, 2009
- Diversity in the contribution of interleukin‐10 to T‐cell‐mediated immune regulationImmunological Reviews, 2008
- Tissue-targeted therapy of autoimmune diabetes using dendritic cells transduced to express IL-4 in NOD miceClinical Immunology, 2008
- Selective delivery of β cell antigen to dendritic cells in vivo leads to deletion and tolerance of autoreactive CD8 + T cells in NOD miceProceedings of the National Academy of Sciences, 2008
- Sustained antigen presentation can promote an immunogenic T cell response, like dendritic cell activationProceedings of the National Academy of Sciences, 2007
- Dendritic cell subsets and type I diabetes: Focus upon DC-based therapyAutoimmunity Reviews, 2006
- Regulatory T Cell Lineage Specification by the Forkhead Transcription Factor Foxp3Immunity, 2005
- Regulatory Th2 response induced following adoptive transfer of dendritic cells in prediabetic NOD miceEuropean Journal of Immunology, 2002
- A Pilot Clinical Trial of HIV Antigen-Pulsed Allogeneic and Autologous Dendritic Cell Therapy in HIV-Infected PatientsAIDS Research and Human Retroviruses, 1998
- Effect of interleukin‐10 on dendritic cell maturation and functionEuropean Journal of Immunology, 1997